Microbot Medical stock price target maintained at $12 by H.C. Wainwright
H.C. Wainwright maintained a $12 price target for Microbot Medical (MBOT) after new patent approvals in the U.S., Japan, China, and Canada. The stock is near its 52-week low at $0.95. Q2 2026 revenue grew 100% to $241,000, but net loss widened to $5.6 million. The company signed a distribution deal in Israel and aims for European market entry.
How this was made
The 30-second read
Why it matters
The patent approvals broaden IP protection, while the Q2 revenue beat adds modest momentum. Analyst confidence may attract speculative buying.
Market read
New patents and earnings beat provide fresh catalyst for MBOT, but small scale limits broader market impact.
What to watch
Potential regulatory delays for CE Mark and reliance on a single product line.
Background
Microbot Medical is a micro‑cap medical‑device firm with a single FDA‑cleared robotic system for peripheral procedures.
Ticker impact
Microbot Medical reported new patent approvals in four countries and Q2 2026 revenue of $241,000, prompting H.C. Wainwright to maintain a $12 price target.
likely upward pressure as market prices in the $12 target and patent news
Patents expand product protection and revenue growth, while the analyst's target implies a 1200% upside from current price.
Market effects
Strengthens outlook for the peripheral endovascular device sector.
Positive for U.S. and Asian med‑tech investors.
Limited to niche medical‑device niche.
Counterpoint
The company’s large net loss and modest revenue may limit near‑term upside despite the high target.
Key entities
- analystH.C. Wainwright
Maintains Buy rating and $12 price target.
- executiveRachel Vaknin
CFO whose salary was increased.
